Cited by 139Sarcoma Diagnosis and TreatmentWnt/β-catenin signaling in development and cancerCancer Cells and Metastasis

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma

Open access

Zhao, S, Kurenbekova, L, Gao, Y, Roos, A, Creighton, C J, Rao, P, Hicks, J, Man, T-K, Lau, C, Brown, A M C, Jones, S N, Lazar, A J, Ingram, D, Lev, D, Donehower, L A, Yustein, J T·2015·Oncogene

DOI 10.1038/onc.2014.429PMC PMC4802362

Open this paper in CoChat — free account

Abstract

Osteosarcoma (OS) is the most frequent pediatric malignant bone tumor that has a high propensity for metastases. Through osteoblast-specific alteration of p53 status, we developed a genetically engineered mouse model of localized and metastatic OS to gain an understanding into the molecular pathogenesis of OS. Microarray analysis of both localized tumors and metastatic tumors identified the downregulation of the naked cuticle homolog 2 (NKD2) gene, a negative regulator of Wnt signaling. Overexpression of NKD2 in metastatic human and mouse OS cells significantly decreases cell proliferation, migration and invasion ability in vitro and drastically diminishes OS tumor growth and metastasis in vivo, whereas downregulation enhances migratory and invasive potential. Evaluation of NKD2-overexpressing tumors revealed upregulation of tumor-suppressor genes and downregulation of molecules involved in blood vessel formation and cell migration. Furthermore, assessment of primary human OS revealed downregulation of NKD2 in metastatic and recurrent OS. Finally, we provide biological evidence that use of small-molecule inhibitors targeting the Wnt pathway can have therapeutic efficacy in decreasing metastatic properties in OS. Our studies provide compelling evidence that downregulation of NKD2 expression and alterations in associated regulated pathways have a significant role in driving OS tumor growth and metastasis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/onc.2014.429

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Self-citation
The Epidemiology of Osteosarcoma
Ottaviani, G., & Jaffe, N. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_1 · Cited by 1,793
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Molenaar, J. J., Köster, J., Zwijnenburg, D. A., Sluis, P. V., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., et al. (2012) · Nature · doi:10.1038/nature10910 · Cited by 873
Genetic determinants of cancer metastasis
Nguyen, D. X., & Massagué, J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2101 · Cited by 814
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752

Flagged first, then by citations

Show all 48 references

1 of the 48 references couldn’t be matched to a known paper.

Sorted by citations

Decoding myofibroblast origins in human kidney fibrosis
Kuppe, C., Ibrahim, M. M., Kranz, J., Zhang, X., Ziegler, S., Perales-Patón, J., Jansen, J., Reimer, K. C., Smith, J. R., Dobie, R., et al. (2021) · Nature · doi:10.1038/s41586-020-2941-1 · Cited by 769
Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy
Cersosimo, F., Lonardi, S., Bernardini, G., Telfer, B., Mandelli, G. E., Santucci, A., Vermi, W., & Giurisato, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155207 · Cited by 280
Molecular genetics of osteosarcoma
Rickel, K., Fang, F., & Tao, J. (2016) · Bone · doi:10.1016/j.bone.2016.10.017 · Cited by 255
Osteosarcoma: Accelerating Progress Makes for a Hopeful Future
Saraf, A. J., Fenger, J. M., & Roberts, R. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00004 · Cited by 237
Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy
Angulo, P., Kaushik, G., Subramaniam, D., Dandawate, P. R., Neville, K. A., Chastain, K. M., & Anant, S. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0373-z · Cited by 191
cBAF complex components and MYC cooperate early in CD8+ T cell fate
Guo, A., Huang, H., Zhu, Z., Chen, J., Shi, H., Yuan, S., Sharma, P., Connelly, J. P., Liedmann, S., Dhungana, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-04849-0 · Cited by 169
Self-citation
Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NKD2 expression
Nie, F., Yu, X., Huang, M., Wang, Y., Xie, M., Ma, H., Wang, Z., De, W., & Sun, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9611 · Cited by 155
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group
Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127
Molecular mechanisms underpinning sarcomas and implications for current and future therapy
Damerell, V., Pepper, M. S., & Prince, S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00647-8 · Cited by 120
Wnt Signaling in Osteosarcoma
Lin, C. H., Ji, T., Chen, C., & Hoang, B. H. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_2 · Cited by 114
Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation
Bhardwaj, A., Yang, Y., Ueberheide, B. M., & Smith, S. H. (2017) · Nature Communications · doi:10.1038/s41467-017-02363-w · Cited by 105
Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma
Nomura, M., Rainusso, N., Lee, Y.-C., Dawson, B., Coarfa, C., Han, R., Larson, J. L., Shuck, R., Kurenbekova, L., & Yustein, J. T. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz026 · Cited by 99
Self-citation
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)
Schafer, E. S., Rau, R. E., Berg, S. L., Liu, X., Minard, C. G., Bishop, A. J. R., Romero, J. C., Hicks, J. M., Nelson, M. D., Voss, S. D., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28073 · Cited by 89
Self-citation
SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT–receptor complex
Zhao, S.-J., Jiang, Y.-Q., Xu, N.-W., Li, Q., Zhang, Q., Wang, S.-Y., Li, J., Wang, Y.-H., Zhang, Y., Jiang, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.403 · Cited by 89
Self-citation
New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau, G., Morice, S., Rédiní, F., Verrecchia, F., & Royer, B. B.-L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153751 · Cited by 88
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis
Gross, A. C., Cam, H., Phelps, D. A., Saraf, A. J., Bid, H. K., Cam, M., London, C. A., Winget, S. A., Arnold, M. A., Brandolini, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99791 · Cited by 82
From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma
Dean, D. C., Shen, S., Hornicek, F. J., & Duan, Z. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9763-8 · Cited by 86
Cross‐species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma
Allen‐Rhoades, W. A., Kurenbekova, L., Satterfield, L., Parikh, N., Fuja, D. G., Shuck, R. L., Rainusso, N. C., Trucco, M. M., Barkauskas, D. A., Jo, E., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.438 · Cited by 81
Self-citation
A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model
Goldstein, S. D., Trucco, M., Guzman, W. B., Hayashi, M., & Loeb, D. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8522 · Cited by 78
A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas
Deel, M. D., Li, J., Crose, L. E. S., & Linardic, C. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00190 · Cited by 73
Targeting the Wnt/β-catenin pathway in human osteosarcoma cells
Fang, F., VanCleave, A. M., Helmuth, R., de Oliveira, H. T., Rickel, K., Wollenzien, H., Sun, H., Zeng, E., Zhao, J., & Tao, J. (2018) · Oncotarget · doi:10.18632/oncotarget.26377 · Cited by 71
Long noncoding RNA HULC promotes colorectal carcinoma progression through epigenetically repressing NKD2 expression
Yang, X., Huang, C., Peng, C., Hou, J., & Liu, J.-Y. (2016) · Gene · doi:10.1016/j.gene.2016.08.002 · Cited by 69
Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance
Walia, M., Ho, P. M., Taylor, S., Ng, A. J., Gupte, A., Chalk, A. M., Zannettino, A. C. W., Martin, T. J., & Walkley, C. R. (2016) · eLife · doi:10.7554/elife.13446 · Cited by 55
Deciphering signaling networks in osteosarcoma pathobiology
Adamopoulos, C., Gargalionis, A. N., Basdra, E. K., & Papavassiliou, A. G. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216648806 · Cited by 51
Matrix‐Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis
Zandueta, C., Ormazabal, C., Perurena, N., Martínez-Canarias, S., Zalacaín, M., San-Julián, M., Grigoriadis, A. E., Valencia, K., Campos-Laborie, F. J., Rivas, J. D. L., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4740 · Cited by 51
Wnt Signaling in Osteosarcoma
Singla, A. K., Wang, J., Yang, R., Geller, D. S., Loeb, D. M., & Hoang, B. H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_8 · Cited by 51
Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation
Chen, J., Zaal, E. A., Berkers, C. R., Ruijtenbeek, R., Garssen, J., & Redegeld, F. A. (2021) · Cells · doi:10.3390/cells10092287 · Cited by 50
Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential
Techavichit, P., Gao, Y., Kurenbekova, L., Shuck, R. L., Donehower, L. A., & Yustein, J. T. (2016) · BMC Cancer · doi:10.1186/s12885-016-2909-6 · Cited by 50
Self-citation
Chrysophanol, a main anthraquinone from Rheum palmatum L. (rhubarb), protects against renal fibrosis by suppressing NKD2/NF-κB pathway
Gu, M., Zhou, Y., Liao, N., Wei, Q., Bai, Z., Bao, N., Zhu, Y., Zhang, H., Gao, L., & Cheng, X. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154381 · Cited by 47
Molecular pathogenesis and therapeutic strategies of human osteosarcoma
Denduluri, S. K., Wang, Z., Yan, Z., Wang, J., Wei, Q., Mohammed, M. K., Haydon, R. C., Luu, H. H., & He, T. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.29.20150075 · Cited by 45
Identification and analysis of key genes in osteosarcoma using bioinformatics
Diao, C., Xi, Y., & Xiao, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.7649 · Cited by 45
Identification of Key Genes Affecting Results of Hyperthermia in Osteosarcoma Based on Integrative ChIP-Seq/TargetScan Analysis
Shi, Y., Yang, F., Wei, S., & Xu, G. (2017) · Medical Science Monitor · doi:10.12659/msm.901191 · Cited by 44
Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors
Pridgeon, M. G., Grohar, P. J., Steensma, M. R., & Williams, B. O. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0377-9 · Cited by 44
Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling
Cao, B., Yang, W., Jin, Y., Zhang, M., He, T., Zhan, Q., Herman, J. G., Zhong, G., & Guo, M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.015 · Cited by 43
Early methionine availability attenuates T cell exhaustion
Sharma, P., Guo, A., Poudel, S., Boada-Romero, E., Verbist, K., Palacios, G., Immadisetty, K., Chen, J., Haydar, D., Mishra, A., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02223-6 · Cited by 45
RETRACTED: LINC00922 regulates epithelial-mesenchymal transition, invasive and migratory capacities in breast cancer through promoting NKD2 methylation
Wang, Y., Dong, T., Wang, P., Li, S., Wu, G., Zhou, J., & Wang, Z. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109808 · Cited by 42
Retracted
Osteoblast-Specific Wnt Secretion Is Required for Skeletal Homeostasis and Loading-Induced Bone Formation in Adult Mice
Lawson, L. Y., Brodt, M. D., Migotsky, N., Chermside‐Scabbo, C. J., Palaniappan, R., & Silva, M. J. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4445 · Cited by 44
Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth
Dong, Y., Cao, B., Zhang, M., Han, W., Herman, J. G., Fuks, F., Zhao, Y., & Guo, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4244 · Cited by 41
Old Mice Have Less Transcriptional Activation But Similar Periosteal Cell Proliferation Compared to Young-Adult Mice in Response to in vivo Mechanical Loading
Chermside‐Scabbo, C. J., Harris, T. L., Brodt, M. D., Brænne, I., Zhang, B., Farber, C. R., & Silva, M. J. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4031 · Cited by 41
Involvement of long non-coding RNA HULC (highly up-regulated in liver cancer) in pathogenesis and implications for therapeutic intervention
Klec, C., Gutschner, T., Panzitt, K., & Pichler, M. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1570499 · Cited by 40
The multiple function of long noncoding RNAs in osteosarcoma progression, drug resistance and prognosis
Xu, S., Gong, Y., Yin, Y., Xing, H., & Zhang, N. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110141 · Cited by 40
NUDT2 Disruption Elevates Diadenosine Tetraphosphate (Ap4A) and Down-Regulates Immune Response and Cancer Promotion Genes
Marriott, A. S., Vasieva, O., Fang, Y., Copeland, N. A., McLennan, A. G., & Jones, N. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154674 · Cited by 40
Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma
Hayashi, M., Baker, A. C., Goldstein, S. D., Albert, C. M., Jackson, K. W., McCarty, G., Kahlert, U. D., & Loeb, D. M. (2017) · Oncotarget · doi:10.18632/oncotarget.19432 · Cited by 37
miR-130b targets NKD2 and regulates the Wnt signaling to promote proliferation and inhibit apoptosis in osteosarcoma cells
Li, Z., Li, Y., Wang, N., Yang, L., Zhao, W., & Zeng, X. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.050 · Cited by 34
Silencing NKD2 by promoter region hypermethylation promotes gastric cancer invasion and metastasis by up-regulating SOX18 in human gastric cancer
Jia, Y., Cao, B., Yang, Y., Linghu, E., Zhan, Q., Lu, Y., Yu, Y., Herman, J. G., & Guo, M. (2015) · Oncotarget · doi:10.18632/oncotarget.5272 · Cited by 33
Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery
Simpson, S., Rizvanov, A. A., Jeyapalan, J. N., de Brot, S., & Rutland, C. S. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.965391 · Cited by 38
Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes
Wang, H., Li, Y., Lv, N., Li, Y., Wang, L., & Yu, L. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3464-9 · Cited by 32
Genetic Factors Conferring Metastasis In Osteosarcoma
Maximov, V. V., & Aqeilan, R. I. (2016) · Future Oncology · doi:10.2217/fon-2016-0014 · Cited by 30
MYC regulates CSF1 expression via microRNA 17/20a to modulate tumor-associated macrophages in osteosarcoma
Nirala, B. K., Patel, T. D., Kurenbekova, L., Shuck, R. L., Dasgupta, A., Rainusso, N. C., Coarfa, C., & Yustein, J. T. (2023) · JCI Insight · doi:10.1172/jci.insight.164947 · Cited by 30
Self-citation
Direct conversion of osteosarcoma to adipocytes by targeting TNIK
Hirozane, T., Masuda, M., Sugano, T., Sekita, T., Goto, N., Aoyama, T., Sakagami, T., Uno, Y., Moriyama, H., Sawa, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.137245 · Cited by 24
Functional interplay between long non-coding RNAs and the Wnt signaling cascade in osteosarcoma
He, J., Ling, L., Liu, Z., Ren, X., Wan, L., Tu, C., & Li, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02013-8 · Cited by 25
Molecular Characterisation of Canine Osteosarcoma in High Risk Breeds
Simpson, S., Dunning, M., de Brot, S., Alibhai, A. A., Bailey, C., Woodcock, C. L., Mestas, M., Akhtar, S., Jeyapalan, J. N., Lothion‐Roy, J. H., et al. (2020) · Cancers · doi:10.3390/cancers12092405 · Cited by 26
Multi‐genic pattern found in rare type of hypopituitarism: a whole‐exome sequencing study of Han Chinese with pituitary stalk interruption syndrome
Guo, Q., Wang, C., Wu, Z., Qin, Y., Han, B., Wang, A., Wang, B., Dou, J., Wu, X., & Mu, Y. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13272 · Cited by 24
Zinc finger antisense 1: A long noncoding RNA with complex roles in human cancers
Jiang, X., Yang, Z., & Li, Z. (2018) · Gene · doi:10.1016/j.gene.2018.11.075 · Cited by 24
miR-181c associates with tumor relapse of high grade osteosarcoma
Mori, F., Sacconi, A., Canu, V., Ganci, F., Novello, M., Anelli, V., Covello, R., Ferraresi, V., Muti, P. C., Biagini, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3539 · Cited by 21
Coamplification of M yc/ P vt1 and homozygous deletion of N lrp1 locus are frequent genetics changes in mouse osteosarcoma
Rao, P. H., Zhao, S., Zhao, Y., Yu, A., Rainusso, N. C., Trucco, M. M., Allen‐Rhoades, W. A., Satterfield, L., Fuja, D. G., Borra, V. J., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22291 · Cited by 22
Self-citation
FH535 Suppresses Osteosarcoma Growth In Vitro and Inhibits Wnt Signaling through Tankyrases
Gustafson, C. T., Mamo, T., Shogren, K. L., Maran, A., & Yaszemski, M. J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00285 · Cited by 23
Epigenetic silencing of the Wnt antagonist APCDD1 by promoter DNA hyper-methylation contributes to osteosarcoma cell invasion and metastasis
Han, W., & Liu, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.049 · Cited by 21
Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells
Cao, F., Nguyen, P., Hong, B., DeRenzo, C. C., Rainusso, N. C., Rodríguez-Cruz, T., Wu, M., Liu, H., Song, X., Suzuki, M., et al. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.99 · Cited by 21
Self-citation
Inhibition of PDT-induced PGE2 surge for enhanced photo-immunotherapy
Liu, X., Huang, J., Zhou, H., Wang, S., Guo, X., Mao, J., Li, X., Lu, Y., Du, Y., Yang, F., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123116 · Cited by 20
Novel Thienopyrimidine Derivative, RP-010, Induces β-Catenin Fragmentation and Is Efficacious against Prostate Cancer Cells
Amawi, H. A., Hussein, N. A., Boddu, S. H. S., Karthikeyan, C., Williams, F. E., Ashby, C. R., Raman, D., Trivedi, P., & Tiwari, A. K. (2019) · Cancers · doi:10.3390/cancers11050711 · Cited by 18
Identification of key genes as predictive biomarkers for osteosarcoma metastasis using translational bioinformatics
Ding, F.-P., Tian, J., Wu, J., Han, D., & Zhao, D. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02308-w · Cited by 18
Knockdown of SALL4 Inhibits Proliferation, Migration, and Invasion in Osteosarcoma Cells
Zhang, D., Jiang, F., Wang, X., & Li, G. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14772402056137 · Cited by 17
Targeting Signaling Pathway by Curcumin in Osteosarcoma
Asemi, Z., Yousefi, B., Farnood, P. R., & Pazhooh, R. D. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220408104341 · Cited by 16
Expression pattern and clinical significance of β-catenin gene and protein in patients with primary malignant and benign bone tumors
Khademian, N., Mirzaei, A., Hosseini, A., Zare, L., Nazem, S., Babaheidarian, P., Sheikhi, A., Abdolvahabi, Z., Ibrahimi, M., Jamshidi, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13685-1 · Cited by 16
Low expression of NKD2 is associated with enhanced cell proliferation and poor prognosis in human hepatocellular carcinoma
Wang, D., Zhang, S., Chen, Y., Hu, B., & Lu, C. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.09.016 · Cited by 15
Biological evaluation of mitochondria targeting small molecules as potent anticancer drugs
Luo, S., Dang, X., Wang, J., Chang, Y., Hu, Y., Lei, S., Zhang, Y., Lü, D., Jiang, F., & Fu, L. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105055 · Cited by 13
Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors
Li, Z., Junzhe, Z., Tang, J., & Wang, R. (2016) · Oncotarget · doi:10.18632/oncotarget.12756 · Cited by 15
Transglutaminase-2 promotes metastatic and stem-like phenotypes in osteosarcoma.
Fuja, D. G., Rainusso, N. C., Shuck, R. L., Kurenbekova, L., Donehower, L. A., & Yustein, J. T. (2018) · Europe PMC (PubMed Central) · Cited by 15
Self-citation
Metastasis-Initiating Osteosarcoma Subpopulations Establish Paracrine Interactions with Lung and Tumor Cells to Create a Metastatic Niche
Reinecke, J. B., Garcia, L. J., Saraf, A. J., Hinckley, J., Gross, A. C., Pommellet, H. L., Gutpell, K. M., Cam, M., Cannon, M. V., Gust, M. J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3360 · Cited by 13
Epigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia
Li, X., Zhou, J., Zhang, T., Yang, L., Wen, X., Ma, J., Yang, J. C., Zhang, Z., Lin, J., & Qian, J. (2017) · Journal of Cancer · doi:10.7150/jca.16914 · Cited by 13
miRNA‐34c Suppresses Osteosarcoma Progression In Vivo by Targeting Notch and E2F
Bae, Y., Zeng, H., Chen, Y., Ketkar, S., Munivez, E. M., Yu, Z., Gannon, F. H., & Lee, B. (2022) · JBMR Plus · doi:10.1002/jbm4.10623 · Cited by 12
Identification of Osteosarcoma Metastasis-Associated Gene Biomarkers and Potentially Targeted Drugs Based on Bioinformatic and Experimental Analysis
Cao, M., Song, Y., Yang, Z., Wang, D., Lin, Y., & Lu, H. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s256617 · Cited by 12
Retracted
Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis
Тодосенко, Н. М., Хлусов, И. А., Yurova, K. A., Хазиахматова, О. Г., & Litvinova, L. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108993 · Cited by 13
The role of lncRNA and miRNA on the effects of occurrence and development of osteosarcoma
Zhang, X., Gao, X., Xu, J., Zhang, Z., Lin, T., Zhang, X., & Kang, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113726 · Cited by 11
Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia
Zhou, J., Yao, D., Han, L., Xiao, G.-F., Guo, H. Y., Zhang, T., Li, X., Yuan, Q., Yang, L., Lin, J., et al. (2017) · Tumor Biology · doi:10.1177/1010428317699123 · Cited by 10
Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma
Nasarre, P., Garcia, D. I., Siegel, J. B., Bonilla, I. V., Mukherjee, R. D., Hilliard, E., Chakraborty, P., Nasarre, C., Yustein, J. T., Lang, M., et al. (2021) · Cancers · doi:10.3390/cancers13112696 · Cited by 11
Self-citation
Logistic regression analysis for the identification of the metastasis-associated signaling pathways of osteosarcoma
Liu, Y., Sun, W. Y., Ma, X., Hao, Y., Liu, G., Hu, X., Shang, H., Wu, P., Zhao, Z., & Liu, W. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3360 · Cited by 10
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma
Ringwalt, E. M., Currier, M. A., Glaspell, A. M., Chen, C., Cannon, M. V., Cam, M., Gross, A. C., Gust, M. J., Wang, P.-Y., Boon, L., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200886 · Cited by 9
Transcriptome of Lung Cancer Cells Resistant to the Cytotoxic Activity of Macrophages
Kovaleva, O. V., Алексеевна, П. П., Vasileva, M., Kopnin, P., Balkin, A. S., Plotnikov, A. O., Kushlinskii, N. E., & Gratchev, A. N. (2022) · Doklady Biochemistry and Biophysics · doi:10.1134/s160767292205009x · Cited by 9
Network model integrated with multi-omic data predicts MBNL1 signals that drive myofibroblast activation
Nelson, A. R., Bugg, D., Davis, J., & Saucerman, J. J. (2023) · iScience · doi:10.1016/j.isci.2023.106502 · Cited by 9
Blocking fatty acid synthase inhibits tumor progression of human osteosarcoma by regulating the human epidermal growth factor receptor 2/phosphoinositide 3-kinase/protein kinase B signaling pathway in xenograft models
Chen, X. Y., Ruan, H. B., Long, X. H., Peng, A. F., Zhou, L., Liu, J. M., Zhou, Y., & Liu, Z. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4284 · Cited by 9
Downregulation of NKD1 in human osteosarcoma and its clinical significance
Chen, X., Xu, P., Zhu, J., & Liu, F. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7968 · Cited by 9
Nkd2 promotes the differentiation of dental follicle stem/progenitor cells into osteoblasts
Chen, C., Zhan, J., Ling, J., Du, Y., & Hou, Y. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3822 · Cited by 9
Silencing of estrogen receptor β promotes the invasion and migration of osteosarcoma cells through activating Wnt signaling pathway
Zhang, Y., Yin, C., Xufeng, Z., Wu, Y., & Wang, L. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s219222 · Cited by 9
LINC00922: A Critical Oncogenic Long Non‐Coding RNA Involved in Cancer Progression, Chemotherapy Resistance, and microRNA Regulation
Si, J., Liang, C., Zhang, X., Xu, H., Su, X., Liu, L., Yuan, R., Ding, Y., & Duan, S. (2025) · Medicine Advances · doi:10.1002/med4.70018 · Cited by 8
Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
Byrgazov, K., Anderson, C. N., Salzer, B., Bozsaky, E., Larsson, R. L., Gullbo, J., Lehner, M., Lehmann, F., Slipicevic, A., Kager, L., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937891 · Cited by 8
Expression and prognostic significance of NKD2 in ovarian cancer
Wei, W., Zheng, L., Gao, Y., He, M., & Yang, F. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa244 · Cited by 7
Self-citation
In Vitro and In Vivo Characterization of a Preclinical Irradiation-Adapted Model for Ewing Sarcoma
Shapiro, M. C., Tang, T. T., Dasgupta, A., Kurenbekova, L., Shuck, R. L., Gaber, M. W., & Yustein, J. T. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.01.095 · Cited by 7
Self-citation
MicroRNA‑1236‑3p inhibits human osteosarcoma growth
Li, J., Chen, J., Hu, Z., & Xu, W. (2020) · Oncology Letters · doi:10.3892/ol.2020.12229 · Cited by 7
LRRC15-CAR T Cells for the Treatment of Osteosarcoma
O'Reilly, C., Tuladhar, S., Nguyen, P. T., Sheppard, H., Koo, S. C., Chockley, P. J., Houke, H., Santiago, T., Tian, L., Jeschke, J., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2335 · Cited by 6
Self-citation
Gliosarcomas lack BRAFV600E mutation, but a subset exhibit β‐catenin nuclear localization
Schwetye, K. E., Joseph, N. M., Al‐Kateb, H., Rich, K. M., Schmidt, R. E., Perry, A., Gutmann, D. H., & Dahiya, S. M. (2016) · Neuropathology · doi:10.1111/neup.12293 · Cited by 6
Machine learning-based prediction of diagnostic markers for Graves’ orbitopathy
Cai, Y., Su, H., Si, Y., & Ni, N. (2023) · Endocrine · doi:10.1007/s12020-023-03349-z · Cited by 6
Copy number variation in archival melanoma biopsies versus benign melanocytic lesions
Mahas, A., Potluri, K., Kent, M. N., Naik, S., & Markey, M. P. (2016) · Cancer Biomarkers · doi:10.3233/cbm-160600 · Cited by 7
Preclinical models for the study of pediatric solid tumors: focus on bone sarcomas
Petrescu, D. I., Yustein, J. T., & Dasgupta, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1388484 · Cited by 5
Self-citation
NKD2 as a Mediator of IFIX Antioncogene‐Induced Wnt Signalling and Epithelial–Mesenchymal Transition in Human OSCC
Wang, S., Li, F., Fan, H., & Bai, J. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70342 · Cited by 5
Dynein: A Multifaceted Therapeutic Target and Its Dysregulation in Aberrant Cell Proliferation
Garg, J., & Alisaraie, L. (2025) · Cytoskeleton · doi:10.1002/cm.22041 · Cited by 5
Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma
Wedekind, M. F., Miller, K. E., Chen, C., Wang, P.-Y., Hutzen, B. J., Currier, M. A., Nartker, B. A., Roberts, R. D., Boon, L., Conner, J., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102759 · Cited by 5
NKD2 mediates stimulation-dependent ORAI1 trafficking to augment Ca2+ entry in T cells
Wu, B., Woo, J. S., Vila, P., Jew, M., Leung, J., Sun, Z., Srikanth, S., & Gwack, Y. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109603 · Cited by 5

Authors: Zhao, S., Kurenbekova, L., Gao, Y., Roos, A., Creighton, C. J., Rao, P., Hicks, J., Man, T.-K., Lau, C., Brown, A. M. C., Jones, S. N., Lazar, A. J., Ingram, D., Lev, D., Donehower, L. A., & Yustein, J. T.
Affiliations: Baylor College of Medicine (US)
Weill Cornell Medicine (US)
University of Massachusetts Chan Medical School (US)
The University of Texas MD Anderson Cancer Center (US)
The Ohio State University (US)
Corresponding author: Yustein, J T
ORCID: Zhao, S
Kurenbekova, L
Creighton, C J
Rao, P
Hicks, J
Man, T-K
Lau, C
Brown, A M C
Lazar, A J
Ingram, D
Yustein, J T
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2015-01-12
Volume: 34
Issue: 39
Pages: 5069-5079
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2014.429
PMC: PMC4802362
OpenAlex: W2069275038
Cited by: 139
References: 48
Citations by year: 2026: 8 · 2025: 10 · 2024: 7 · 2023: 6 · 2022: 13 · 2021: 15 · 2020: 14 · 2019: 11 · 2018: 10 · 2017: 17 · 2016: 18 · 2015: 8
FWCI: 13.99
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA123238, P30CA125123)
National Institute of General Medical Sciences (T32GM008539)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: NKD2, osteosarcoma, Wnt signaling, metastasis, tumor growth, cell migration, cell invasion, p53, genetically engineered mouse models, tumor suppressor, angiogenesis, recurrent osteosarcoma, Wnt pathway inhibitors
MeSH terms: Animals, Bone Neoplasms, Calcium-Binding Proteins, Carrier Proteins, Neoplasm Invasiveness, Neoplasm Metastasis, Osteosarcoma, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Cell Proliferation, Mice, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks